Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|7|896-901

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.7, 2015-07, pp. : 896-901

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ginkgetin inhibits the growth of DU−145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 413-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1714-1721

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1561-1567

John Wiley & Sons Inc

Access to resources Recommend Favorite